Trade

with

Vanda Pharmaceuticals Inc
(NASDAQ: VNDA)
AdChoices
10.33
+0.30
+2.99%
After Hours :
10.33
+0.00
+0.01%

Open

10.24

Previous Close

10.03

Volume (Avg)

1.04M (512.85k)

Day's Range

10.09-10.71

52Wk Range

5.70-19.25

Market Cap.

349.96M

Dividend Rate ( Yield )

-

Beta

1.89

Shares Outstanding

33.88M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 33.88M

    • Net Income

    • -20.26M

    • Market Cap.

    • 349.96M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -161.24

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.89

    • Forward P/E

    • -24.57

    • Price/Sales

    • 9.11

    • Price/Book Value

    • 400.00

    • Price/Cash flow

    • -4.01

      • EBITDA

      • -18.47M

      • Return on Capital %

      • -59.53

      • Return on Equity %

      • -2,045.71

      • Return on Assets %

      • -59.53

      • Book Value/Share

      • 0.03

      • Shares Outstanding

      • 33.88M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 12.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.46

        • Cashflow Estimate

        • 0.18

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 30.60

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 99.47

            • 82.75

            • Pre-Tax Margin

            • -161.24

            • 39.38

            • Net Profit Margin

            • -161.24

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 85.60

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -187.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -188.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 1.86

              • 2.92

              • Quick Ratio

              • 1.72

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 97.37

              • 2.21

              • Book Value/Share

              • 0.03

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.51

                • 243.90

                • P/E Ratio 5-Year High

                • -10.53

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.60

                • 124.82

                • Price/Sales Ratio

                • 8.89

                • 9.29

                • Price/Book Value

                • 384.62

                • 8.39

                • Price/Cash Flow Ratio

                • -4.01

                • 49.75

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -2,045.71

                        (-62.00)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -59.53

                        (-11.90)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -2,045.71

                        (-62.00)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 0.18

                      • 1.48

                      • Asset Turnover

                      • 0.37

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -20.40M
                      Operating Margin
                      -60.21
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -4.01
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      80.01%

                      Mutual Fund Ownership

                      46.66%

                      Float

                      76.30%

                      5% / Insider Ownership

                      2.36%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • T. Rowe Price Health Sciences Fund

                      •  

                        2,150,813

                      • 89.93

                      • 6.35

                      • Fidelity® Select Health Care Portfolio

                      •  

                        1,997,624

                      • 17.51

                      • 5.90

                      • SPDR® S&P Biotech ETF

                      •  

                        1,283,359

                      • -9.83

                      • 3.66

                      • Invesco Global Health Care Fd

                      •  

                        865,662

                      • 0.00

                      • 2.56

                      • Fidelity VIP Growth Portfolio

                      •  

                        607,810

                      • -25.70

                      • 1.79

                      • Vanguard Total Stock Mkt Idx

                      •  

                        555,528

                      • 0.00

                      • 1.64

                      • iShares Russell 2000 (AU)

                      •  

                        510,823

                      • -1.81

                      • 1.46

                      • CREF Stock

                      •  

                        488,116

                      • -2.70

                      • 1.44

                      • iShares Nasdaq Biotechnology

                      •  

                        440,352

                      • -0.24

                      • 1.26

                      • Fidelity Advisor® Health Care Fund

                      •  

                        428,729

                      • 14.84

                      • 1.27

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity Management and Research Company

                      •  

                        4,569,496

                      • +1.20%

                      • 13.49

                      • Baker Bros Advisors LLC

                      •  

                        4,372,153

                      • -1.65%

                      • 12.91

                      • T. Rowe Price Associates, Inc.

                      •  

                        3,426,791

                      • +95.61%

                      • 10.12

                      • Palo Alto Investors, LLC

                      •  

                        3,240,424

                      • -49.61%

                      • 9.57

                      • Paulson & Company Inc

                      •  

                        3,200,000

                      • +129.80%

                      • 9.45

                      • Kingdon Capital Management LLC

                      •  

                        1,740,400

                      • +50.82%

                      • 5.14

                      • State Street Corp

                      •  

                        1,551,918

                      • -0.16%

                      • 4.58

                      • BlackRock Fund Advisors

                      •  

                        1,244,343

                      • -6.86%

                      • 3.67

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Growth

                      Vanda Pharmaceuticals, Inc. was incorporated in Delaware in 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central...more nervous system disorders. It operates in one business segment which is the development and commercialization of pharmaceutical products. Its product portfolio includes: HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt, a product for the treatment of schizophrenia, the oral formulation of which is currently being marketed and sold in the U.S. by Novartis Pharma AG; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The Company utilizes a virtual supply manufacturing and distri...morebution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities.lessless

                      Key People

                      Dr. Mihael Hristos Polymeropoulos,M.D.

                      CEO/Co-Founder/Director/President

                      H. Thomas Watkins

                      Chairman of the Board/Director

                      Mr. James Patrick Kelly

                      CFO/Chief Accounting Officer/Secretary/Senior VP/Treasurer

                      Richard W. Dugan

                      Director

                      Vincent J. Milano

                      Director

                      • Vanda Pharmaceuticals Inc

                      • 2200 Pennsylvania Avenue NW

                      • Washington, DC 20037

                      • USA.Map

                      • Phone: +1 202 734-3400

                      • Fax: +1 202 296-1450

                      • vandapharmaceuticals.com

                      Incorporated

                      2002

                      Employees

                      53

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: